TR200400650T3 - Antidiyabetik maddeler ve antiobezite maddeleri olarak yararlı ikame edilmiş azol asit türevleri ve yöntem - Google Patents
Antidiyabetik maddeler ve antiobezite maddeleri olarak yararlı ikame edilmiş azol asit türevleri ve yöntemInfo
- Publication number
- TR200400650T3 TR200400650T3 TR2004/00650T TR200400650T TR200400650T3 TR 200400650 T3 TR200400650 T3 TR 200400650T3 TR 2004/00650 T TR2004/00650 T TR 2004/00650T TR 200400650 T TR200400650 T TR 200400650T TR 200400650 T3 TR200400650 T3 TR 200400650T3
- Authority
- TR
- Turkey
- Prior art keywords
- agents
- acid derivatives
- derivatives useful
- substituted azole
- antidiabetic
- Prior art date
Links
- 239000000883 anti-obesity agent Substances 0.000 title abstract 2
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 229940125710 antiobesity agent Drugs 0.000 title abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 229940125708 antidiabetic agent Drugs 0.000 title 1
- 150000003851 azoles Chemical class 0.000 title 1
- 239000003623 enhancer Substances 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000055 hyoplipidemic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 210000002824 peroxisome Anatomy 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29438001P | 2001-05-30 | 2001-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200400650T3 true TR200400650T3 (tr) | 2004-06-21 |
Family
ID=23133159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2004/00650T TR200400650T3 (tr) | 2001-05-30 | 2002-05-23 | Antidiyabetik maddeler ve antiobezite maddeleri olarak yararlı ikame edilmiş azol asit türevleri ve yöntem |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20030092736A1 (https=) |
| EP (1) | EP1390363A4 (https=) |
| JP (1) | JP2004536070A (https=) |
| AU (1) | AU2002259306B2 (https=) |
| CA (1) | CA2449160A1 (https=) |
| CZ (1) | CZ20033230A3 (https=) |
| DE (1) | DE02729306T1 (https=) |
| ES (1) | ES2214168T1 (https=) |
| HU (1) | HUP0401504A3 (https=) |
| MX (1) | MXPA03010997A (https=) |
| NO (1) | NO327089B1 (https=) |
| PE (1) | PE20030043A1 (https=) |
| PL (1) | PL367066A1 (https=) |
| TR (1) | TR200400650T3 (https=) |
| TW (1) | TWI235061B (https=) |
| UY (1) | UY27316A1 (https=) |
| WO (1) | WO2002096358A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003256419A1 (en) * | 2002-08-21 | 2004-03-11 | Merck & Co., Inc. | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
| EP1424070A1 (en) * | 2002-11-28 | 2004-06-02 | Fournier Laboratories Ireland Limited | Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| US7601756B2 (en) * | 2003-06-06 | 2009-10-13 | Snowden Pharmaceuticals, Llc | Method of treatment for irritable bowel syndrome |
| JP2009513523A (ja) | 2003-07-08 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物 |
| ES2390053T3 (es) * | 2003-09-22 | 2012-11-06 | Ono Pharmaceutical Co., Ltd. | Derivado de ácido fenilacético, procedimiento para producir el mismo y uso |
| EP1734953A4 (en) * | 2004-03-02 | 2008-08-20 | Abeille Pharmaceuticals Inc | CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS |
| ES2282062T1 (es) | 2004-06-04 | 2007-10-16 | Teva Pharmaceutical Industries Ltd. | Composicion farmaceutica que contiene irbesartan. |
| CN1304393C (zh) * | 2004-07-01 | 2007-03-14 | 中国药科大学 | 取代的吡唑啉酮衍生物及其制备方法与药用组合物 |
| KR100706600B1 (ko) * | 2004-11-25 | 2007-04-12 | 주식회사 엘지생명과학 | ＰＰＡＲ ｇａｍｍａ와 ＰＰＡＲ ａｌｐｈａ의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물 |
| KR20060058632A (ko) * | 2004-11-25 | 2006-05-30 | 주식회사 엘지생명과학 | ＰＰＡＲ ｇａｍｍａ와 ＰＰＡＲ ａｌｐｈａ의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물 |
| WO2007058504A1 (en) * | 2005-11-21 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same |
| US20090048199A1 (en) * | 2007-03-09 | 2009-02-19 | Hiberna Corporation | Hibernation-Related Genes and Proteins, Activators and Inhibitors Thereof and Methods of Use |
| BRPI0822349A2 (pt) * | 2007-11-29 | 2019-09-24 | Neuraltus Pharmaceuticals Inc | composições e métodos para tratar doenças lisossômicas |
| CN102256493A (zh) * | 2008-10-29 | 2011-11-23 | 迪赛孚尔制药有限公司 | 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN109498622A (zh) * | 2018-12-28 | 2019-03-22 | 成都恒瑞制药有限公司 | 一种氯沙坦钾与罗格列酮组合物及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| US5591862A (en) * | 1993-06-11 | 1997-01-07 | Takeda Chemical Industries, Ltd. | Tetrazole derivatives, their production and use |
| EP1177176B1 (en) * | 1999-04-28 | 2006-04-19 | Aventis Pharma Deutschland GmbH | Tri-aryl acid derivatives as ppar receptor ligands |
| US6506781B1 (en) * | 1999-09-08 | 2003-01-14 | Smithkline Beecham Corporation | Oxazole PPAR antagonist |
| HK1045991B (en) * | 1999-11-10 | 2004-12-10 | Takeda Pharmaceutical Company Limited | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| EP1394154A4 (en) * | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE |
-
2002
- 2002-05-22 US US10/153,454 patent/US20030092736A1/en not_active Abandoned
- 2002-05-23 EP EP02729306A patent/EP1390363A4/en not_active Withdrawn
- 2002-05-23 CA CA002449160A patent/CA2449160A1/en not_active Abandoned
- 2002-05-23 MX MXPA03010997A patent/MXPA03010997A/es active IP Right Grant
- 2002-05-23 CZ CZ20033230A patent/CZ20033230A3/cs unknown
- 2002-05-23 TR TR2004/00650T patent/TR200400650T3/xx unknown
- 2002-05-23 ES ES02729306T patent/ES2214168T1/es active Pending
- 2002-05-23 DE DE0001390363T patent/DE02729306T1/de active Pending
- 2002-05-23 JP JP2002592871A patent/JP2004536070A/ja active Pending
- 2002-05-23 HU HU0401504A patent/HUP0401504A3/hu unknown
- 2002-05-23 WO PCT/US2002/016633 patent/WO2002096358A2/en not_active Ceased
- 2002-05-23 PL PL02367066A patent/PL367066A1/xx not_active Application Discontinuation
- 2002-05-23 AU AU2002259306A patent/AU2002259306B2/en not_active Ceased
- 2002-05-24 TW TW091111100A patent/TWI235061B/zh not_active IP Right Cessation
- 2002-05-30 UY UY27316A patent/UY27316A1/es not_active Application Discontinuation
- 2002-05-30 PE PE2002000455A patent/PE20030043A1/es not_active Application Discontinuation
-
2003
- 2003-11-28 NO NO20035312A patent/NO327089B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002096358A2 (en) | 2002-12-05 |
| ES2214168T1 (es) | 2004-09-16 |
| PL367066A1 (en) | 2005-02-21 |
| TWI235061B (en) | 2005-07-01 |
| HUP0401504A3 (en) | 2008-05-28 |
| DE02729306T1 (de) | 2004-08-26 |
| PE20030043A1 (es) | 2003-02-05 |
| JP2004536070A (ja) | 2004-12-02 |
| UY27316A1 (es) | 2002-12-31 |
| EP1390363A4 (en) | 2011-01-05 |
| MXPA03010997A (es) | 2004-02-27 |
| EP1390363A2 (en) | 2004-02-25 |
| NO20035312D0 (no) | 2003-11-28 |
| CA2449160A1 (en) | 2002-12-05 |
| CZ20033230A3 (cs) | 2004-02-18 |
| NO327089B1 (no) | 2009-04-20 |
| HUP0401504A2 (hu) | 2004-11-29 |
| AU2002259306B2 (en) | 2007-02-08 |
| US20030092736A1 (en) | 2003-05-15 |
| WO2002096358A3 (en) | 2003-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200400650T3 (tr) | Antidiyabetik maddeler ve antiobezite maddeleri olarak yararlı ikame edilmiş azol asit türevleri ve yöntem | |
| DE69823344D1 (de) | Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen | |
| ATE275134T1 (de) | 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel | |
| NO923695L (no) | Leukotrien-biosyntese-inhibitorer | |
| NL350077I1 (nl) | Cyprosulfamide | |
| TR200200732T2 (tr) | Antidiyabetik ve antiobesite maddeleri olarak faydalı oksa-ve tiyazol türevleri | |
| ATE236890T1 (de) | Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer | |
| DE69918422D1 (de) | Phthalazinone pde iii/iv hemmer | |
| DE69817802D1 (de) | Substituierte phenylderivate, ihre herstellung und verwendung | |
| DK1109817T3 (da) | Phosphohalogenhydriner, deres fremstilling og anvendelse | |
| DK1042319T3 (da) | Dihydrobenzofuraner | |
| IT1315267B1 (it) | Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale | |
| BRPI0210746B8 (pt) | derivados de 6-'2-(fosfonometóxi)alcóxi-pirimidina e seu método de preparação | |
| NO20062629L (no) | Oksazolderivater av tetrackliner | |
| DE60311887D1 (de) | Multifunktionelle kationische photoinitiatoren, deren herstellung und verwendung | |
| BRPI0412446A (pt) | compostos de silicio e seu uso | |
| TR200101945T2 (tr) | Benzoksazol türevleri ve aktif içeriğin aynı içerikli ilaçları | |
| AU2001242430A1 (en) | Use of 2-phenylene diamine derivatives for the treatment of infections | |
| ATE254131T1 (de) | Benzimidazolderivate | |
| BR0002514A (pt) | Derivados de 4-arilpiperidina para o tratamento de prurido | |
| NO20020291L (no) | Terapeutiske og profylaktiske midler for neoplasmer | |
| CY1106317T1 (el) | Παραγωγα 1-ν-φαινυλαμινο-1η-ιμιδαζολης, ως αναστολεις αρωματασης | |
| ATE374778T1 (de) | Organosiliziumverbindungen und deren verwendung | |
| DE69522955D1 (de) | Okulares hypotensium | |
| DE69943259D1 (de) | Neue 2-Halogen-Derivate von 5-O-Desosaminylerythronolid A, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |